Table 1 incidence of ocular morbidity during 2 year fixed MDT by patient*.

Ocular conditions	No of patients†	Patient years	Events	Incidence rate per person year	95% CI
Lid conditions
Orbicularis oculi weakness	276	432.13	10	0.023	0.013 to 0.043
Lagophthalmos	277	436.55	5	0.012	0.005 to 0.028
Ectropion	287	450.67	5	0.011	0.005 to 0.027
Trichiasis	286	451.68	5	0.011	0.005 to 0.027
Conjunctival conditions
Nasolacrimal duct block	284	448.33	4	0.009	0.003 to 0.024
Pterygium	252	392.31	15	0.038	0.023 to 0.063
B663 crystals	288	452.64	4	0.009	0.003 to 0.024
Corneal conditions
Corneal opacity	258	394.20	29	0.074	0.051 to 0.106
Corneal nerve beading	283	440.94	12	0.027	0.016 to 0.048
Punctate keratitis‡	284	447.18	6	0.013	0.006 to 0.030
Uveal conditions
Flare and cell	287	452.59	2	0.004	0.001 to 0.018
Keratic precipitates	273	424.53	13	0.031	0.018 to 0.053
Irregular pupil	285	447.95	5	0.011	0.005 to 0.027
Iris atrophy	283	441.53	9	0.020	0.011 to 0.039
Any uveal involvement¶	268	410.87	21	0.051	0.033 to 0.078
Cataract
Cataract	221	328.49	34	0.104	0.074 to 0.145
Cataract with vision of 6/18 or less	257	394.88	17	0.043	0.027 to 0.069
Grouped
LROP	247	373.14	37	0.099	0.072 to 0.137
PBLROP	258	394.65	23	0.058	0.039 to 0.088

*MDT, multidrug therapy; B663, clofazamine crystals in cornea or conjunctiva. †The number of patients at risk for each event is based on the number of patients who were event free at the initiation of MDT and who had at least one follow up examination visit. ‡Neurotrophic or exposure related . ¶Any uveal involvement includes flare and cell, keratic precipitates and iris atrophy. LROP, leprosy related ocular pathology includes muscle weakness, lagophthalmos, ectropion, entropion, trichiasis, episcleritis, scleritis, corneal nerve beading, punctate keratitis, and uveal involvement. PBLROP, potentially blinding leprosy related ocular pathology includes lagophthalmos and/or uveal involvement.